FDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral Adrenoleukodystrophy Genetics Investing
Cesca Therapeutics’ Chief Technology Officer, Phil Coelho, Provides Deep Dive into the CAR-T Manufacturing Process in Cell & Gene Therapy Genetics Investing
International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 2018 Genetics Investing
Cesca Therapeutics Announces First Quarter 2018 Financial Results and Provides Corporate Update Genetics Investing